Clinical Trials Addressing Unmet Needs of Rare Neurodegenerative Diseases (R01) Clinical Trials Required
Last verified by NonDilute: 2026-04-29. Official notice and agency instructions control.
If you have a promising therapy for a rare neurological disorder and access to patient populations, this grant funds the clinical evidence needed to move toward FDA approval.
Report stale or inaccurate summary
What this is
This NIH/FDA-partnered R01 mechanism supports clinical research addressing gaps in treatment options for rare neurodegenerative disorders. The funding requires applicants to design and conduct human clinical trials (not preclinical work) that meet FDA standards for safety and efficacy data. This is a competitive, research-intensive award best suited to institutions with clinical trial infrastructure, patient access, and regulatory expertise. The CFDA code 93.103 indicates NIH funding managed through health research channels.
Who can apply
Typically eligible applicants include academic medical centers, research universities, and established biotech/pharma firms with clinical trial infrastructure and regulatory capability. Solo founders and very small teams are unlikely to qualify without institutional affiliation. Specific eligibility (citizenship, nonprofit status, geographic limits) not stated in provided text; consult full RFP or NIH grants.gov listing.
Topics: rare neurodegenerative disease · clinical trial · R01 grant · FDA approval · unmet medical need
Public-source funding discovery only. This summary is generated from public agency data and may be incomplete or stale. NonDilute is not affiliated with, endorsed by, or acting on behalf of any government agency. Official notices and agency instructions control. NonDilute does not determine eligibility, provide grant-writing advice, or guarantee funding.